Ameritas Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ameritas Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,564	Closed	-$14K	–	2185
2025 Q2	$14K	Buy	+1,564	New	+$14.6K	﹤0.01%	1882
2023 Q2	–	Sell	-1,244	Closed	-$9.69K	–	722
2023 Q1	$9.69K	Buy	+1,244	New	+$12K	﹤0.01%	1905

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Advisory Services's BCRX Position: Q3 2025 in Review

Ameritas Advisory Services sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 1,564 shares — an estimated $14K sold.

Ameritas Advisory Services first reported a position in BCRX in Q1 2023 and held it in 2 quarters. The position peaked at $14K in Q2 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Ameritas Advisory Services reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Ameritas Advisory Services sold 1,564 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $14K.
Ameritas Advisory Services first reported a position in BioCryst Pharmaceuticals in Q1 2023 and held it in 2 quarters.
Ameritas Advisory Services's BioCryst Pharmaceuticals position peaked at $14K in Q2 2025.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.